Chinese researchers from the Southern University of Science and Technology have achieved a significant breakthrough in neuroimaging technology with the development of PACMes, an innovative photoacoustic imaging system that enables long-term, high-resolution brain monitoring in mice without surgical intervention or contrast agents.
The pioneering technology, detailed in a recent publication in Science Advances, addresses longstanding challenges in brain imaging where the scalp and skull typically cause substantial interference through light refraction, optical scattering, and acoustic attenuation. The PACMes system achieves synergistic optimization across three critical dimensions: near-infrared optical excitation, low-frequency acoustic detection, and advanced computational reconstruction.
This integrated approach facilitates efficient penetration through intact biological barriers while minimizing scattering interference and ensuring high-sensitivity, full-angle detection of photoacoustic signals. The system produces isotropic high-resolution imaging across the entire field of view, covering a 13-millimeter diameter area that encompasses the complete mouse cerebral cortex with exceptional 33-micrometer spatial resolution.
A remarkable feature of PACMes is its capacity for continuous monitoring exceeding five months, providing unprecedented opportunities for longitudinal studies. In practical application, the system successfully tracked vascular changes in a mouse model of mild ischemic stroke throughout a five-month observation period. Crucially, the technology non-invasively identified the formation of new collateral circulation in the infarct area 72 hours post-modeling—a key pathological feature that offers direct insight into vascular repair mechanisms following stroke.
The research team emphasizes that this technology represents an ideal platform for monitoring chronic progression of various brain disorders. The innovation holds particular promise for advancing research into cerebrovascular conditions including Alzheimer’s disease and epilepsy, potentially opening new avenues for investigating disease mechanisms and evaluating therapeutic interventions.